[go: up one dir, main page]

TR200103405T2 - Bifunctional antibodies and their use in targeting tumor-inhibiting agents. - Google Patents

Bifunctional antibodies and their use in targeting tumor-inhibiting agents.

Info

Publication number
TR200103405T2
TR200103405T2 TR2001/03405T TR200103405T TR200103405T2 TR 200103405 T2 TR200103405 T2 TR 200103405T2 TR 2001/03405 T TR2001/03405 T TR 2001/03405T TR 200103405 T TR200103405 T TR 200103405T TR 200103405 T2 TR200103405 T2 TR 200103405T2
Authority
TR
Turkey
Prior art keywords
inhibiting agents
bifunctional antibodies
targeting tumor
treatment
targeting
Prior art date
Application number
TR2001/03405T
Other languages
Turkish (tr)
Inventor
John Harrison Peter
Original Assignee
Ks Biomedix Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ks Biomedix Ltd. filed Critical Ks Biomedix Ltd.
Publication of TR200103405T2 publication Critical patent/TR200103405T2/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31Immunoglobulins specific features characterized by aspects of specificity or valency multispecific

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Bir iki islevli antikar bir hedef mahalline yönelik olarak birlesme egilimine ve bir sitotoksik amile ya da bir ön ilaci bunun kendisine iat sitotiksik biçim içerisine dönüstürme yeterliliginde olan bir bir enzime kovalent olarak baglanmis olan bir organik moleküle yönelik olarak birlesme egilimine sahip bulunmaktadir. Ankikor, tedavi ya da teshiste, özellikle de, tümörlerin tedavi edilmesinde kullanilabilmektedir.A bi-functional antibody has a tendency to fuse for a target site and an organic molecule covalently linked to a cytotoxic agent or an enzyme capable of converting a prodrug into a cytotic form thereof. Ankikor can be used in treatment or diagnosis, especially in the treatment of tumors.

TR2001/03405T 1998-09-04 1999-09-06 Bifunctional antibodies and their use in targeting tumor-inhibiting agents. TR200103405T2 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9819411.1A GB9819411D0 (en) 1998-09-04 1998-09-04 Antibodies

Publications (1)

Publication Number Publication Date
TR200103405T2 true TR200103405T2 (en) 2002-06-21

Family

ID=10838416

Family Applications (2)

Application Number Title Priority Date Filing Date
TR2001/03405T TR200103405T2 (en) 1998-09-04 1999-09-06 Bifunctional antibodies and their use in targeting tumor-inhibiting agents.
TR2001/00651T TR200100651T2 (en) 1998-09-04 1999-09-06 Bifunctional antibodies and their use in targeting tumor-inhibiting agents

Family Applications After (1)

Application Number Title Priority Date Filing Date
TR2001/00651T TR200100651T2 (en) 1998-09-04 1999-09-06 Bifunctional antibodies and their use in targeting tumor-inhibiting agents

Country Status (20)

Country Link
EP (1) EP1107995A2 (en)
JP (1) JP2002524470A (en)
KR (1) KR20010072988A (en)
CN (1) CN1315967A (en)
AU (1) AU5641299A (en)
BG (1) BG105293A (en)
BR (1) BR9913429A (en)
CA (1) CA2341753A1 (en)
EA (1) EA200100311A1 (en)
GB (1) GB9819411D0 (en)
HR (1) HRP20010154A2 (en)
HU (1) HUP0104091A2 (en)
ID (1) ID28873A (en)
IL (1) IL141524A0 (en)
MX (1) MXPA01002349A (en)
NO (1) NO20011102L (en)
PL (1) PL346861A1 (en)
TR (2) TR200103405T2 (en)
WO (1) WO2000014119A2 (en)
ZA (1) ZA200101574B (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019227490A1 (en) 2018-06-01 2019-12-05 Tayu Huaxia Biotech Medical Group Co., Ltd. Compositions and methods for imaging
WO2019228514A1 (en) 2018-06-01 2019-12-05 Tayu Huaxia Biotech Medical Group Co., Ltd. Compositions and uses thereof for treating disease or condition
US20210309745A1 (en) * 2018-07-26 2021-10-07 Tayu Huaxia Biotech Medical Group Co., Ltd. Compositions and methods for imaging
WO2020151572A1 (en) 2019-01-23 2020-07-30 Tayu Huaxia Biotech Medical Group Co., Ltd. Anti-pd-l1 diabodies and the use thereof
CN110811820B (en) * 2019-12-11 2022-07-12 江西华晨医疗设备有限公司 Straight rod type flushing and suction electrocoagulation cutter

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4474893A (en) * 1981-07-01 1984-10-02 The University of Texas System Cancer Center Recombinant monoclonal antibodies
IL89491A0 (en) * 1988-11-17 1989-09-10 Hybritech Inc Bifunctional chimeric antibodies
US5217713A (en) * 1988-12-27 1993-06-08 Takeda Chemical Industries, Ltd. Cytotoxic bispecific monoclonal antibody, its production and use
EP0505566A1 (en) * 1989-12-15 1992-09-30 Takeda Chemical Industries, Ltd. Biospecific antibody to cancer cell and enzyme with prodrug-activating characteristics
JPH05184383A (en) * 1990-06-19 1993-07-27 Dainabotsuto Kk Bispecific antibody
WO1998038513A1 (en) * 1997-02-26 1998-09-03 Khaw Ban An Signal enhancement of bispecific antibody-polymer probe for immunoassay use

Also Published As

Publication number Publication date
CN1315967A (en) 2001-10-03
ID28873A (en) 2001-07-12
NO20011102L (en) 2001-03-05
IL141524A0 (en) 2002-03-10
TR200100651T2 (en) 2001-07-23
HRP20010154A2 (en) 2002-02-28
NO20011102D0 (en) 2001-03-02
JP2002524470A (en) 2002-08-06
PL346861A1 (en) 2002-03-11
EP1107995A2 (en) 2001-06-20
BG105293A (en) 2001-12-29
AU5641299A (en) 2000-03-27
WO2000014119A3 (en) 2000-11-30
GB9819411D0 (en) 1998-10-28
KR20010072988A (en) 2001-07-31
WO2000014119A2 (en) 2000-03-16
ZA200101574B (en) 2002-02-26
HUP0104091A2 (en) 2002-03-28
CA2341753A1 (en) 2000-03-16
BR9913429A (en) 2001-09-25
EA200100311A1 (en) 2001-08-27
MXPA01002349A (en) 2003-10-15

Similar Documents

Publication Publication Date Title
ATE383430T1 (en) RECOMBINANT ANTIBODIES AND IMMUNE CONJUGATES TARGETED AT CD22-BEARING CELLS AND TUMORS
EP1071460A4 (en) ERBB2 INTERNALIZATION ANTIBODIES
Krall et al. A small‐molecule drug conjugate for the treatment of carbonic anhydrase IX expressing tumors
DE69830326D1 (en) IMINING POLYSACCHARIDES, THEIR PREPARATION AND USE AS ADDITIVES AND IMMUNOSTIMULATING AGENTS
FI982422A0 (en) Porphyrin compounds, their conjugates and assay methods based on the use of said conjugate
WO2004018000A3 (en) Compositions and methods for treating cancer using maytansinoid cd44 antibody immonoconjugates and chemotherapeutic agents
EA200400179A1 (en) TREATMENT AND DIAGNOSTIC CANCER
CY1111863T1 (en) OPTIONS AGAINST DEATH RECEPTOR 4 (DR4) AND THEIR USES
EP2357006A3 (en) Drug conjugates and their use for treating cancer, an autoimmune disease or an infectious disease
CY1113370T1 (en) ADMINISTRATIVE MEDICINE PREPARATION CONSIDERED BY A CELLULAR AND A MALLEMINAL GROUP CONNECTED TO AN INTERMEDIATE
DE60033658D1 (en) TREATMENT OF PROSTATE CANCER WITH ANTI-ERBB2 ANTIBODIES
DE69737867D1 (en) TARGETED COMBINATION IMMUNOTHERAPY FOR CANCER
IL187389A0 (en) Nucleic acid molecule encoding a conjugate for treating activated immune cells
TR200003161T2 (en) Polyol-IFN-Beta conjugates
ATE415979T1 (en) TREATMENT WITH ANTI-ERBB2 ANTIBODIES
AR035977A1 (en) IMMUNOCONJUGADOS OF ANTIBODIES CD44 CITOTOXICOS.
RU92016354A (en) COMPOSITION, METHODS OF TREATMENT, METHOD OF PREVENTION OF RECURRENCE, METHOD OF ENHANCING CYTOTOXIC ACTIVITY OF IMMUNOTOXIN, METHOD OF ENHANCING CYTOTOXIC ACTION OF CONJUGATE
ATE304709T1 (en) SUBSTANCES WITH BRANCHED LINKER MOLECULES
FI924605A0 (en) ANTIKROPPONJUGATER FOER BEHANDLING AV NEOPLASTISKA SJUKDOMAR
TR200102041T2 (en) 2-arylmino heterocycles substituted as progesterone receptor binding agents
ATE192047T1 (en) BICYLCLIC, POLYAZAMACROCYCLOCARBOXYLIC ACID COMPLEXES, CONJUGATES, PREPARATION AND USE AS CONTRAST MATERIALS
TR200103405T2 (en) Bifunctional antibodies and their use in targeting tumor-inhibiting agents.
DE69921486D1 (en) DEXTRAN-LEPTIN CONJUGATES, PHARMACEUTICAL COMPOSITIONS AND RELATED METHODS
Maison et al. Improved chemical strategies for the targeted therapy of cancer
TR200102944T2 (en) Integrin receptor ligands